ALSO NOTED: GW Pharma to get Sativex review; BMS wins priority review;and much more...

> The UK's GW Pharmaceuticals says that Canadian regulators will consider approving its cannabis-based Sativex as a therapy for cancer pain. Report

> The FDA has given priority review status to Bristol-Myers Squibb's breast cancer drug ixabepilone. Report

> Roche and Chugai plan basic new research of Tamiflu in the wake of reports in Japan that the drug has been linked to abnormal behavior. Report

> Javelin Pharmaceuticals says that a late-stage study of its pain drug Rylomine demonstrated a reduction in postsurgical orthopedic pain. Report

And Finally… Richard Friedman, M.D., discusses how genetic testing may soon take much of the guesswork out of prescribing antidepressants. Article